1. The Syk–NFAT–IL-2 Pathway in Dendritic Cells Is Required for Optimal Sterile Immunity Elicited by Alum Adjuvants
- Author
-
Hanif Javanmard Khameneh, Adrian W. S. Ho, Alessandra Mortellaro, Hazel Quek, Roberto Spreafico, and Heidi Derks
- Subjects
CD4-Positive T-Lymphocytes ,0301 basic medicine ,T cell ,Phagocytosis ,Immunology ,Syk ,Enzyme-Linked Immunosorbent Assay ,chemical and pharmacologic phenomena ,Biology ,Lymphocyte Activation ,Immune Regulation ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Immune system ,Adjuvants, Immunologic ,Immunity ,Adjuvanticity ,medicine ,Animals ,Syk Kinase ,Immunology and Allergy ,NFATC Transcription Factors ,Alum ,NFAT ,Dendritic Cells ,Flow Cytometry ,Mice, Inbred C57BL ,030104 developmental biology ,medicine.anatomical_structure ,chemistry ,Models, Animal ,Alum Compounds ,Interleukin-2 ,Signal Transduction ,030215 immunology - Abstract
Despite a long history and extensive usage of insoluble aluminum salts (alum) as vaccine adjuvants, the molecular mechanisms underpinning Ag-specific immunity upon vaccination remain unclear. Dendritic cells (DCs) are crucial initiators of immune responses, but little is known about the molecular pathways used by DCs to sense alum and, in turn, activate T and B cells. In this article, we show that alum adjuvanticity requires IL-2 specifically released by DCs, even when T cell secretion of IL-2 is intact. We demonstrate that alum, as well as other sterile particulates, such as uric acid crystals, induces DCs to produce IL-2 following initiation of actin-mediated phagocytosis that leads to Src and Syk kinase activation, Ca2+ mobilization, and calcineurin-dependent activation of NFAT, the master transcription factor regulating IL-2 expression. Using chimeric mice, we show that DC-derived IL-2 is required for maximal Ag-specific proliferation of CD4+ T cells and optimal humoral responses following alum-adjuvanted immunization. These data identify DC-derived IL-2 as a key mediator of alum adjuvanticity in vivo and the Src–Syk pathway as a potential leverage point in the rational design of novel adjuvants.
- Published
- 2017
- Full Text
- View/download PDF